Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03100045 · ClinicalTrials.gov registry record · Phase 1
Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)
A Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT03100045: Completed Phase 1 study, sponsored by Johns Hopkins University.
NCT03100045 is a Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03100045, a Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This open label study investigates a novel non-surgical approach to the treatment of HPV-associated anal intraepithelial neoplasia, using Artesunate suppositories.
Interventions
- DRUG Artesunate Suppositories
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2017-04-20 |
| Est. Completion | 2021-10-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03100045
The ClinicalTrials.gov registry entry for NCT03100045 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Artesunate Suppositories is the first listed.
NCT03100045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03100045 about?
NCT03100045 is a clinical study titled "Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)". This open label study investigates a novel non-surgical approach to the treatment of HPV-associated anal intraepithelial neoplasia, using Artesunate suppositories.
What is the current status of trial NCT03100045?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2017-04-20. Estimated completion is 2021-10-06.
What interventions are being tested in trial NCT03100045?
The interventions under investigation include: Artesunate Suppositories (DRUG).
Who is sponsoring clinical trial NCT03100045?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.